Table S1 – Phenotypes not differing between WT and Δ*cprS*

	Phenotype	Experiment
Pathogenesis-related:	Adherence and invasion	*in vitro* INT 407 gentamicin protection assay
	Serum sensitivity	10% human serum survival
Antimicrobial tolerance:	Antibiotic resistance:	MICs: gentamicin, ampicillin, rifampicin
	Antimicrobial tolerance:	MICs: Tween-20, Triton X-100, ethidium bromide, EDTA
	Low pH survival	acetic acid disk diffusion assay, MH broth pH 5.5 survival
Atmospheric tolerance:	Aerobic atmosphere survival	ambient atmosphere broth culture survival
	Anaerobic atmosphere survival	anaerobic atmosphere broth culture survival
	Oxidative sensitivity	30% H_2O_2 disk diffusion assay
	Low CO_2 tolerance	5% CO_2 atmosphere growth
Carbohydrates:	Surface polysaccharides	Calcofluor white, Congo red, and Sudan black reactivity
	Lipooligosaccharide	SDS-PAGE - silver stain profile
	Capsule	SDS-PAGE - Alcian blue staining and Penner immunoblotting
Nutritional stress:	Low iron (Fe^{2+} and Fe^{3+})	dipyridyl and desferal sensitivity
	Nutritional downshift	survival in Minimal Essential media
Other:	Heat shock	growth at 45°C
	Low osmotic tolerance	survival in water

Table S2. Strains used in this study.

C. jejuni strains		
81-176	wildtype	Korlath *et al.*, 1985
Δ*cprS*	81-176 *cprS*::Cm^R derivative	this study
Δ*cprS*::KmR	81-176 *cprS*::Kan^R derivative	this study
Δ*cprS*^{C}	81-176 *cprS*::Cm^R *rrn*::*cprS*	this study
Δ*spoT*	81-176 *spoT*::Kan^R	Gaynor *et al.* 2005
E. coli strains		
DH5a	general cloning strain, *recA1 endA1*	Invitrogen
Bacteriomatch II	two-hybrid *HIS3* and *aadA* reporter strain	Stratagene
Plasmids		
pCR-XL-TOPO	PCR cloning vector, Km^R	Invitrogen
pGEM-T	PCR cloning vector, Amp^R	Promega
pJM1	*cprS*::CmR in pCR-XL-TOPO	this study
pJM2	*cprR*::CmR in pCR-XL-TOPO	this study
pSS3	*cprS*::KmR in pGEM-T	this study
pRRK	*C. jejuni* rRNA spacer integration vector, Km^R	J. Ketley
pSS50	*cprS* in pRRK, KmR	this study
pBT	two-hybrid lambda cI fusion vector, Cm^R	Stratagene
pTRG	two-hybrid RNAP-α fusion vector, Km^R	Stratagene
pSS38	*cprS* C-terminal domain in pTRG	this study
pSS39	*dccR* in pBT	this study
pSS41	*cprR* in pBT	this study

Table S3. Primers used in this study

Primer name	Sequence (5' -> 3')	Restriction site	Source
cprS-TOPO FWD	GTTTCAAGCGCAAGACAT	-	this study
cprS-TOPO REV	GAGCTTAAGGAGCGTTTGGA	-	this study
cprS-INV FWD	TAAGCCACAAAAAGCCAAGT	*Mfe* I	this study
cprS-INV REV	AATCAAGTTTTGGATTAGGGCTTT	*Mfe* I	this study
cprS-pGEM FWD	GTCTGGATCCGTTTTGCGACTTTGCTTGTGC	*Bam* HI	this study
cprS-pGEM REV	GTGTCTCGAGTACTCTACCGCTGAGCTAATCCG	*Xho* I	this study
cprS-INV2 FWD	GCAGTCTAGAGAAATGATAGAAGATAATAAATATAAAGAGCG	*Xba* I	this study
cprS-INV2 REV	GTAAGGTACCGCCAAGTATAACACTAACCCCAGC	*Kpn* I	this study
cprS-pRRC FWD	GCTCTAGAGGTTATAAGCTTACTCAATGAATAAATC	*Xba* I	this study
cprS-pRRC REV	GCCAATTGTTACTCCTTAACAATAACACTTTTTAAATTTC	*Mfe* I	this study
ak233	GCAAGAGTTTTGCTTATGTTAGCAC	-	Karlyshev and Wren, 2005
ak234	GAAATGGGCAGAGTGTATTCTCCG	-	Karlyshev and Wren, 2005
ak235	GTGCGGATAATGTTGTTTCTG	-	Karlyshev and Wren, 2005
PKanF	CAAGTGGTATGACATTGCCTTCTG	-	J. Ketley
BT-*cprR* FWD	GATCGGATCCATGACAAATATTCTTATGATAGAAGATGATT	*Bam* HI	this study
BT-*cprR* REV	GTACACTAGTTCATTGAGTAAGCTTATAACCTATTCC	*Spe* I	this study
BT-*dccR* FWD	GATCGGATCCATGGCTGCTAAAATTTTACTTTTAG	*Bam* HI	this study
BT-*dccR* REV	GTACACTAGTTTAGCCATAGCAATATCCCCTG	*Spe* I	this study
TRG-*cprS*-CTD FWD	GATCGGATCCATGGGGGTGGATGAAATTTC	*Bam* HI	this study
TRG-*cprS*-CTD REV	GTACCTCGAGTTACTCCTTAACAATAACACTTTTTAAATTT	*Xho* I	this study
htrA-3'	GTTCAAGTGCTGATGAAGCAGG	-	this study